Phase 2 Double Blind Randomized Placebo Controlled Trial of Topical Crisaborole in Patients with Mild-to-Moderate Alopecia Areata
Latest Information Update: 30 Oct 2024
At a glance
- Drugs Crisaborole (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
Most Recent Events
- 06 Jan 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 25 May 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 25 May 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Mar 2022.